Morgan Stanley Maxcyte, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Maxcyte, Inc. stock. As of the latest transaction made, Morgan Stanley holds 7,025,463 shares of MXCT stock, worth $8.92 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,025,463

Previous 7,000,799 0.35%

Holding current value

$8.92 Million

Previous $19.1 Million 19.87%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$2.04 - $2.92 $50,314 - $72,018	24,664 Added 0.35%	7,025,463 $15.3 Million
Q1 2025 May 15, 2025	BUY	$2.73 - $5.1 $7.08 Million - $13.2 Million	2,592,546 Added 58.81%	7,000,799 $19.1 Million
Q4 2024 Feb 14, 2025	SELL	$3.23 - $4.43 $1.32 Million - $1.81 Million	-408,879 Reduced 8.49%	4,408,253 $18.3 Million
Q3 2024 May 14, 2025	BUY	$3.68 - $5.06 $654,929 - $900,528	177,970 Added 3.84%	4,817,132 $18.7 Million
Q3 2024 Nov 14, 2024	BUY	$3.68 - $5.06 $654,929 - $900,528	177,970 Added 3.84%	4,817,132 $18.7 Million
Q2 2024 May 14, 2025	BUY	$3.63 - $5.0 $838,199 - $1.15 Million	230,909 Added 5.24%	4,639,162 $18.2 Million
Q2 2024 Oct 17, 2024	BUY	$3.63 - $5.0 $4.07 Million - $5.6 Million	1,120,046 Added 31.83%	4,639,162 $18.2 Million
Q2 2024 Aug 14, 2024	BUY	$3.63 - $5.0 $4.07 Million - $5.6 Million	1,120,046 Added 31.83%	4,639,162 $18.2 Million
Q1 2024 Oct 17, 2024	SELL	$3.94 - $5.38 $4.41 Million - $6.03 Million	-1,120,046 Reduced 24.14%	3,519,116 $14.7 Million
Q1 2024 Aug 16, 2024	BUY	$3.94 - $5.38 $150,137 - $205,010	38,106 Added 1.09%	3,519,116 $14.7 Million
Q1 2024 May 15, 2024	BUY	$3.94 - $5.38 $150,137 - $205,010	38,106 Added 1.09%	3,519,116 $14.7 Million
Q4 2023 Aug 16, 2024	SELL	$2.6 - $5.24 $3.01 Million - $6.07 Million	-1,158,152 Reduced 24.96%	3,481,010 $16.4 Million
Q4 2023 Feb 13, 2024	BUY	$2.6 - $5.24 $5.61 Million - $11.3 Million	2,155,840 Added 162.68%	3,481,010 $16.4 Million
Q3 2023 Nov 15, 2023	SELL	$3.02 - $5.1 $896,477 - $1.51 Million	-296,847 Reduced 18.3%	1,325,170 $4.13 Million
Q2 2023 Aug 14, 2023	SELL	$3.69 - $5.35 $217,163 - $314,858	-58,852 Reduced 3.5%	1,622,017 $7.45 Million
Q1 2023 May 15, 2023	BUY	$4.03 - $5.89 $485,002 - $708,849	120,348 Added 7.71%	1,680,869 $8.32 Million
Q4 2022 Feb 14, 2023	BUY	$4.92 - $7.4 $350,697 - $527,472	71,280 Added 4.79%	1,560,521 $8.52 Million
Q3 2022 Nov 14, 2022	SELL	$4.52 - $6.51 $296,507 - $427,049	-65,599 Reduced 4.22%	1,489,241 $9.68 Million
Q2 2022 Oct 27, 2022	BUY	$3.59 - $6.81 $907,778 - $1.72 Million	252,863 Added 19.42%	1,554,840 $7.35 Million
Q2 2022 Aug 15, 2022	BUY	$3.59 - $6.81 $907,778 - $1.72 Million	252,863 Added 19.42%	1,554,840 $7.35 Million
Q1 2022 Oct 27, 2022	SELL	$5.26 - $10.84 $1.33 Million - $2.74 Million	-252,863 Reduced 16.26%	1,301,977 $9.1 Million
Q1 2022 May 13, 2022	SELL	$5.26 - $10.84 $390,544 - $804,848	-74,248 Reduced 5.4%	1,301,977 $9.1 Million
Q4 2021 Feb 14, 2022	BUY	$8.87 - $12.94 $727,570 - $1.06 Million	82,026 Added 6.34%	1,376,225 $14 Million
Q3 2021 Nov 15, 2021	BUY	$12.21 - $17.2 $15.8 Million - $22.3 Million	1,294,199 New	1,294,199 $15.8 Million

Others Institutions Holding MXCT

# of Institutions

121

Shares Held

71M

Call Options Held

Put Options Held

View Full List

About MAXCYTE, INC.

Ticker MXCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 101,724,000
Market Cap $129M
Description
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...

More about MXCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account